Alto Neuroscience, Inc. Earnings Per Share (Basic)
Alto Neuroscience, Inc. (ANRO) reported Earnings Per Share (Basic) of -$0.65 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-12
- Alto Neuroscience, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.65.
- Alto Neuroscience, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.80.
- Alto Neuroscience, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.47.
- Alto Neuroscience, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.52.
- Alto Neuroscience, Inc. earnings per share, basic for fiscal 2025 was -$2.19.
- Alto Neuroscience, Inc. earnings per share, basic for fiscal 2024 was -$2.50.
- Alto Neuroscience, Inc. earnings per share, basic for fiscal 2023 was -$9.73.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.65 10-Q · filed 2026-08-12 | -$1.34 10-Q · filed 2026-08-12 | -$1.91 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$2.46 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2026-03-31 | -$0.80 10-Q · filed 2026-05-13 | -$1.26 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.80 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$2.45 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2025-12-31 | -$0.47 derived: net income ÷ weighted average shares · filed 2026-03-16 | -$0.99 derived: net income ÷ weighted average shares · filed 2026-03-16 | -$1.63 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$2.19 10-K · filed 2026-03-16 |
| 2025-09-30 | -$0.52 10-Q · filed 2025-11-12 | -$1.18 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.74 10-Q · filed 2025-11-12 | -$2.31 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2025-06-30 | -$0.65 10-Q · filed 2026-08-12 | -$1.21 10-Q · filed 2026-08-12 | -$1.78 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$2.41 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2025-03-31 | -$0.56 10-Q · filed 2026-05-13 | -$1.13 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.75 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$2.35 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2024-12-31 | -$0.57 derived: net income ÷ weighted average shares · filed 2026-03-16 | -$1.19 derived: net income ÷ weighted average shares · filed 2026-03-16 | -$1.79 derived: net income ÷ weighted average shares · filed 2026-03-16 | -$2.50 10-K · filed 2026-03-16 |
| 2024-09-30 | -$0.62 10-Q · filed 2025-11-12 | -$1.22 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$1.94 10-Q · filed 2025-11-12 | -$3.05 derived: net income ÷ weighted average shares · filed 2025-11-12 |
| 2024-06-30 | -$0.60 10-Q · filed 2025-08-13 | -$1.32 10-Q · filed 2025-08-13 | -$2.53 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$3.83 derived: net income ÷ weighted average shares · filed 2025-11-12 |
| 2024-03-31 | -$0.76 10-Q · filed 2025-05-14 | -$2.31 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$4.03 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$5.89 derived: net income ÷ weighted average shares · filed 2025-11-12 |
| 2023-12-31 | -$2.97 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$5.42 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$7.75 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$9.73 10-K · filed 2025-03-20 |
| 2023-09-30 | -$2.44 10-Q · filed 2024-11-12 | -$4.77 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$6.75 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$2.33 10-Q · filed 2024-08-13 | -$4.31 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$1.97 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |